<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726592</url>
  </required_header>
  <id_info>
    <org_study_id>CLORMIG</org_study_id>
    <nct_id>NCT04726592</nct_id>
  </id_info>
  <brief_title>Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room</brief_title>
  <official_title>Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of clorazepate in addition to the usual&#xD;
      medication for treating migraine attack in the emergency room&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will receive the usual migraine treatment: IV ketoprofen 100 mg and, if he&#xD;
      suffers nausea and/or vomiting, additional IV metoclopramide 10 mg.&#xD;
&#xD;
      Depending on randomization assignment, patient will receive additional placebo (standard&#xD;
      treatment arm) or additional IV Clorazepate 20 mg (study arm). The central pharmacy will be&#xD;
      responsible for preparing the medications, using a double-blind protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 8, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>2 hours</time_frame>
    <description>Percentage of patients &quot;pain-relief&quot; 2 hours after administration of the treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Migraine</condition>
  <condition>Migraine Without Aura</condition>
  <condition>Migraine With Aura</condition>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo and standard care :&#xD;
Placebo IV&#xD;
Ketoprofen 100 mg IV (if nausea-vomiting)&#xD;
Metoclopramide 10 mg IV(if nausea-vomiting)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clorazepate and standard care :&#xD;
Clorazepate 20 mg IV&#xD;
Ketoprofen 100 mg IV (if nausea-vomiting)&#xD;
Metoclopramide 10 mg IV(if nausea-vomiting)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clorazepate Dipotassium</intervention_name>
    <description>Clorazepate Dipotassium : 20 mg intravenous injection</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>TRANXENE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoprofen</intervention_name>
    <description>Ketoprofen 100 mg IV</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Metoclopramide 10 mg IV</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age from 18 to 70&#xD;
&#xD;
          -  Patient suffering migraine or probable migraine (diagnosis made by neurologist&#xD;
             according to IHCD3)&#xD;
&#xD;
          -  Present migraine attack lasting ≤ 72 hours&#xD;
&#xD;
          -  Headache intensity moderate or severe on the verbal ordinal scale (4 levels: no&#xD;
             headache, mild, moderate or severe)&#xD;
&#xD;
          -  Patient requiring parenteral treatment&#xD;
&#xD;
          -  Affiliation to the French Health-care System &quot;sécurité sociale&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  abnormalities of neurological exam, seizure, fever (≥ 38°C), and/or SBP≥180 and/or&#xD;
             DBP≥110 mmHg&#xD;
&#xD;
          -  suspicion of secondary headache&#xD;
&#xD;
          -  inability to understand the consent or scales&#xD;
&#xD;
          -  pregnancy or breast-feeding&#xD;
&#xD;
          -  known respiratory or liver insufficiency&#xD;
&#xD;
          -  acute alcohol consumption or alcoholism&#xD;
&#xD;
          -  myasthenia&#xD;
&#xD;
          -  Patient requiering treatment with sumatriptan SC, particularly in the event of failure&#xD;
             of an anti-inflammatory drug at an effective dose taken within 6 hours&#xD;
&#xD;
          -  recent use of benzodiazepines (&lt; 24h diazepam, clonazepam, clorazepate ; &lt; 6h&#xD;
             alprazolam, lorazepam, midazolam)&#xD;
&#xD;
          -  recent use of pain killers (&lt; 2h)&#xD;
&#xD;
          -  contraindication to any of the investigational medication&#xD;
&#xD;
          -  contraindication to intravenous access&#xD;
&#xD;
          -  previous participation to this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jérôme Dr MAWET</last_name>
    <phone>01 49 95 24 77</phone>
    <phone_ext>+33</phone_ext>
    <email>jerome.mawet@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme JM MAWET, Dr</last_name>
      <phone>01 49 95 24 77</phone>
      <phone_ext>+33</phone_ext>
      <email>jerome.mawet@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 24, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
    <mesh_term>Clorazepate Dipotassium</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

